IXEKIZUMAB MAKES VERY LOW DISEASE ACTIVITY AND REMISSION WITH PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS FOR UP TO 1 YEAR: SPIRIT-P1 AND SPIRIT-P2 TRIALS

被引：2
|
作者：
Coates, L. C. [1 ]
Husni, M. E. [2 ]
Lespessailles, E. [3 ]
Kerr, L. [4 ]
Gallo, G. [4 ]
机构：
[1] Univ Leeds, Sch Med, Leeds, W Yorkshire, England
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Orleans Hosp, Orleans, France
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2329
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0314
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [1] LOW DISEASE THRESHOLDS UP TO THREE YEARS IN IXEKI-ZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS IN SPIRIT-P1 AND SPIRIT-P2
    Kavanaugh, A.
    Helliwell, P.
    Sesin, C.
    Gellett, A. M.
    Lin, C-Y.
    Sprabery, A. T.
    Geneus, V.
    Bolce, R.
    Coates, L. C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1221 - 1221
  • [2] The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
    Deodhar, Atul
    Gladman, Dafna
    Bolce, Rebecca
    Sandoval, David
    Park, So Young
    Leage, Soyi Liu
    Nash, Peter
    Poddubnyy, Denis
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
  • [3] INTEGRATED EFFICACY AND SAFETY RESULTS FROM SPIRIT-P1 AND SPIRIT-P2, TWO PHASE 3 TRIALS OF IXEKIZUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Combe, B.
    Nash, P.
    Adams, D.
    Kerr, L.
    Moriarty, S.
    Benichou, O.
    [J]. INTERNAL MEDICINE JOURNAL, 2018, 48 : 41 - 41
  • [4] Integrated Efficacy and Safety Results From SPIRIT-P1 and SPIRIT-P2, Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
    Combe, Bernard
    Nash, Peter
    Adams, David
    Kerr, Lisa
    Moriarty, Susan
    Benichou, Olivier
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 17 - 18
  • [5] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
    Coates, Laura C.
    Mease, Philip
    Kronbergs, Andris
    Helt, Cameron
    Sandoval, David
    Park, So Young
    Combe, Bernard
    Nash, Peter
    Deodhar, Atul
    [J]. CLINICAL RHEUMATOLOGY, 2022, 41 (10) : 3035 - 3047
  • [6] Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
    Laura C. Coates
    Philip Mease
    Andris Kronbergs
    Cameron Helt
    David Sandoval
    So Young Park
    Bernard Combe
    Peter Nash
    Atul Deodhar
    [J]. Clinical Rheumatology, 2022, 41 : 3035 - 3047
  • [7] Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
    Laura C. Coates
    Philip Mease
    Andris Kronbergs
    Cameron Helt
    David Sandoval
    So Young Park
    Bernard Combe
    Peter Nash
    Atul Deodhar
    [J]. Clinical Rheumatology, 2022, 41 : 3261 - 3261
  • [8] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2
    Coates, L. C.
    Kronbergs, A.
    Sprabery, A. T.
    Park, S. Y.
    Combe, B.
    Deodhar, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1153 - 1154
  • [9] Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials
    Tillett, W.
    Lin, C-Y
    Sprabery, A. T.
    Birt, J. A.
    Kavanaugh, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (06) : 1227 - 1230
  • [10] EFFICACY OF IXEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AXIAL PAIN STARTING BEFORE AGE 45: A SUBGROUP ANALYSIS OF SPIRIT-P1 AND SPIRIT-P2 PHASE 3 CLINICAL TRIALS
    Deodhar, Atul
    Ogdie, Alexis
    Muram, Talia
    Sandoval, David
    Geneus, Vladimir
    Nash, Peter
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1838 - 1838
12345